Literature DB >> 1567546

Interleukin-3 and hematopoiesis.

J N Ihle1.   

Abstract

Considerable information has accumulated over the past several years relating to the biological activities of IL-3 which supports that concept that IL-3 has a unique capacity to support the proliferation and differentiation of a wide spectrum of hematopoietic cells. The pleiotropic activity of IL-3 has in turn elicited considerable enthusiasm for clinical trials of IL-3 in humans. Such clinical trials are ongoing and will certainly reveal a variety of conditions that will benefit from IL-3 treatment alone or in combination with other lymphokines. Of particular note are conditions which would benefit from the proliferation and expansion of early myeloid progenitors. These include bone marrow reconstitutions, aplastic anemias, hematopoietic recovery following chemotherapy. A variety of data demonstrate that hematopoiesis is not dependent upon IL-3. Thus, alternative factors must exist that can also support the proliferation and differentiation of hematopoietic stem cells. This observation and the uniquely T cell origin of IL-3 have led to the concept the production of IL-3 has evolved within the immune system as a mechanism by which immunological reactions can broadly affect hematopoiesis. The lack of an essential role in constitutive hematopoiesis would be consistent with the divergence in the structure of the gene that is seen among species. Such a role would also predict that it will be easy to obtain mice in which the gene has been deleted by homologous recombination. Indeed, such mice will be essential to fully define the role that IL-3 has in the development and content of immune responses. Although IL-3 supports the proliferation of a variety of myeloid lineages and cells at various stages of differentiation, relatively little has been uncovered regarding the influence that IL-3 might have no differentiation. The results strongly suggest that IL-3 does not singularly control differentiation. The other extreme would suggest that IL-3 may support proliferation which allows the expression of a genetic program that is determined completely independent of IL-3. The most appealing hypothesis is that IL-3 can influence the outcome of a differentiation program. In particular, it can be hypothesized that a pluripotential stem cell that is proliferating in IL-3 has a somewhat different pattern of differentiation than cells proliferating in the presence of the factors that control constitutive hematopoiesis. Of particular interest are mechanisms by which IL-3 mediates its biological effects.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567546     DOI: 10.1159/000420755

Source DB:  PubMed          Journal:  Chem Immunol        ISSN: 0079-6034


  28 in total

1.  Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.

Authors:  M Kieslinger; I Woldman; R Moriggl; J Hofmann; J C Marine; J N Ihle; H Beug; T Decker
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

2.  p85β regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis.

Authors:  Subha Krishnan; Raghuveer Singh Mali; Baskar Ramdas; Emily Sims; Peilin Ma; Joydeep Ghosh; Veerendra Munugalavadla; Philip Hanneman; Joal D Beane; Reuben Kapur
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

3.  Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.

Authors:  Nana Arai; Mayumi Homma; Maasa Abe; Yuta Baba; So Murai; Megumi Watanuki; Yukiko Kawaguchi; Shun Fujiwara; Nobuyuki Kabasawa; Hiroyuki Tsukamoto; Yui Uto; Hirotsugu Ariizumi; Kouji Yanagisawa; Norimichi Hattori; Bungo Saito; Eisuke Shiozawa; Hiroshi Harada; Toshiko Yamochi-Onizuka; Tsuyoshi Nakamaki; Masafumi Takimoto
Journal:  Int J Hematol       Date:  2019-03-07       Impact factor: 2.490

Review 4.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Andrew D Cook; Paul P Tak
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

Review 5.  An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.

Authors:  Sangeetha Venugopal; Naval Daver; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

6.  IL-3 induces basophil expansion in vivo by directing granulocyte-monocyte progenitors to differentiate into basophil lineage-restricted progenitors in the bone marrow and by increasing the number of basophil/mast cell progenitors in the spleen.

Authors:  Keitaro Ohmori; Yuchun Luo; Yi Jia; Jun Nishida; Zhengqi Wang; Kevin D Bunting; Demin Wang; Hua Huang
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

8.  Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis.

Authors:  F W Quelle; K Shimoda; W Thierfelder; C Fischer; A Kim; S M Ruben; J L Cleveland; J H Pierce; A D Keegan; K Nelms
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

9.  Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction.

Authors:  O Silvennoinen; B A Witthuhn; F W Quelle; J L Cleveland; T Yi; J N Ihle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

10.  Proliferation of multipotent hematopoietic cells controlled by a truncated erythropoietin receptor transgene.

Authors:  S L Kirby; D N Cook; W Walton; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.